Biofrontera Inc. Net Fee Amt
Biofrontera Inc. (BFRI) had Net Fee Amt of $738.83 as of 2026-07-22, per its S-8 filed 2026-07-22.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-07-22
- 2026-07-22: Net Fee Amt $738.83.
| Period end | Net Fee Amt |
|---|---|
| 2026-07-22 | $738.83 S-8 · filed 2026-07-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |